191 related articles for article (PubMed ID: 10992445)
41. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
42. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
[TBL] [Abstract][Full Text] [Related]
43. Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.
Jobe DA; Callister SM; Lim LC; Lovrich SD; Schell RF
J Clin Microbiol; 1994 Mar; 32(3):618-22. PubMed ID: 8195368
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of human Lyme disease vaccine formulations in a mouse model.
Telford SR; Kantor FS; Lobet Y; Barthold SW; Spielman A; Flavell RA; Fikrig E
J Infect Dis; 1995 May; 171(5):1368-70. PubMed ID: 7751719
[TBL] [Abstract][Full Text] [Related]
45. Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes.
Wang Y; Kern A; Boatright NK; Schiller ZA; Sadowski A; Ejemel M; Souders CA; Reimann KA; Hu L; Thomas WD; Klempner MS
J Infect Dis; 2016 Jul; 214(2):205-11. PubMed ID: 27338767
[TBL] [Abstract][Full Text] [Related]
46. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis.
Callister SM; Schell RF
J Infect Dis; 1994 Aug; 170(2):499-500. PubMed ID: 8035047
[No Abstract] [Full Text] [Related]
47. Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice.
Munson EL; DeCoster DJ; Nardelli DT; England DM; Callister SM; Schell RF
Clin Diagn Lab Immunol; 2004 Jan; 11(1):35-41. PubMed ID: 14715542
[TBL] [Abstract][Full Text] [Related]
48. Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease.
Brunet LR; Katavolos P; Spielman A; Telford SR
Med Vet Entomol; 1997 Apr; 11(2):198-200. PubMed ID: 9226653
[No Abstract] [Full Text] [Related]
49. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
[TBL] [Abstract][Full Text] [Related]
50. Role of IL-17, transforming growth factor-beta, and IL-6 in the development of arthritis and production of anti-outer surface protein A borreliacidal antibodies in Borrelia-vaccinated and -challenged mice.
Nardelli DT; Kevin Luk KH; Kotloski NJ; Warner TF; Torrealba JR; Callister SM; Schell RF
FEMS Immunol Med Microbiol; 2008 Jul; 53(2):265-74. PubMed ID: 18522647
[TBL] [Abstract][Full Text] [Related]
51. Protection of mice from Lyme borreliosis by oral vaccination with Escherichia coli expressing OspA.
Fikrig E; Barthold SW; Kantor FS; Flavell RA
J Infect Dis; 1991 Dec; 164(6):1224-7. PubMed ID: 1955724
[TBL] [Abstract][Full Text] [Related]
52. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.
Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; Pêtre J
Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340
[TBL] [Abstract][Full Text] [Related]
53. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease.
Gipson CL; Davis NL; Johnston RE; de Silva AM
Vaccine; 2003 Sep; 21(25-26):3875-84. PubMed ID: 12922122
[TBL] [Abstract][Full Text] [Related]
55. Antibody responses of rats and humans to flagella-less cells and OspA protein of Borrelia burgdorferi.
Sadziene A; Thompson PA; Barbour AG
Ann N Y Acad Sci; 1996 Oct; 797():140-50. PubMed ID: 8993358
[No Abstract] [Full Text] [Related]
56. Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status.
Gomes-Solecki MJ; Wormser GP; Schriefer M; Neuman G; Hannafey L; Glass JD; Dattwyler RJ
J Clin Microbiol; 2002 Jan; 40(1):193-7. PubMed ID: 11773115
[TBL] [Abstract][Full Text] [Related]
57. Vaccination as a modality to prevent Lyme disease. A status report.
Wormser GP
Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
[TBL] [Abstract][Full Text] [Related]
58. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
59. T helper cell priming of mice to Borrelia burgdorferi OspA leads to induction of protective antibodies following experimental but not tick-borne infection.
Zhong W; Gern L; Kramer M; Wallich R; Simon MM
Eur J Immunol; 1997 Nov; 27(11):2942-7. PubMed ID: 9394822
[TBL] [Abstract][Full Text] [Related]
60. Major histocompatibility complex class II-independent generation of neutralizing antibodies against T-cell-dependent Borrelia burgdorferi antigens presented by dendritic cells: regulation by NK and gammadelta T cells.
Mbow ML; Zeidner N; Gilmore RD; Dolan M; Piesman J; Titus RG
Infect Immun; 2001 Apr; 69(4):2407-15. PubMed ID: 11254601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
